Journal article
Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia
Abstract
Lefamulin is a novel oral and intravenous (IV) pleuromutilin developed as a twice-daily treatment for community-acquired bacterial pneumonia (CABP). It is a semi-synthetic pleuromutilin with a chemical structure that contains a tricyclic core of five-, six-, and eight-membered rings and a 2-(4-amino-2-hydroxycyclohexyl)sulfanylacetate side chain extending from C14 of the tricyclic core. Lefamulin inhibits bacterial protein synthesis by binding …
Authors
Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N
Journal
Drugs, Vol. 81, No. 2, pp. 233–256
Publisher
Springer Nature
Publication Date
February 2021
DOI
10.1007/s40265-020-01443-4
ISSN
0012-6667